NCT04195828

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer: an Multicenter, Open, Randomized, Controlled Clinical Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 106 (actual)
• Sponsor: Fujian Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate, nab-paclitaxel and S-1

Conditions

• Advanced Gastric Cancer

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.
DRUG	Apatinib Mesylate	Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。
DRUG	nab-paclitaxel	nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.
DRUG	S1	S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time

Timeline

• Start date: 2020-06-18
• Primary completion: 2022-07-22
• Completion: 2025-03-24
• First posted: 2019-12-12
• Last updated: 2025-04-01

Locations

1 site across 1 country: China